Innovative Use of Spironolactone as an Antiandrogen in the Treatment of Female Pattern Hair Loss
Section snippets
Etiology of FPHL
The hair loss progresses in a highly reproducible pattern. Exposure of genetically susceptible hair follicles to androgen leads to several changes including hair follicle miniaturization and changes in hair cycle dynamics with shortening of anagen duration and prolongation of telogen duration.
Summary
Women find patterned hair loss distressing. The inconvenience of topical therapy and the slow response and the potential for adverse effects with systemic therapy deter many women from pursuing treatment, as does the need for life-long therapy. Nevertheless, most women who do embark on treatment tolerate the medications well and satisfactorily arrest further hair loss. Many also achieve a moderate degree of hair regrowth that is sustained for the duration of the treatment. Women with FPHL who
References (58)
Female pattern hair loss
J Am Acad Dermatol
(2001)- et al.
Androgenetic alopecia in men and women
Clin Dermatol
(2001) - et al.
Prevalence of male and female pattern hair loss in Maryborough
J Investig Dermatol Symp Proc
(2005) - et al.
Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects
J Am Acad Dermatol
(1993) - et al.
Polymorphism of the androgen receptor gene is associated with male pattern baldness
J Invest Dermatol
(2001) - et al.
The inheritance of common baldness. Two B or not two B?
J Am Acad Dermatol
(1984) - et al.
Different levels of 5 alpha reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia
J Invest Dermatol
(1997) - et al.
Androgen insensitivity syndrome
Baillieres Clin Endocrinol Metab
(1994) - et al.
Role of androgen in mesenchymal epithelial interactions in human hair follicle
J Investig Dermatol Symp Proc
(2005) - et al.
Finasteride in the treatment of men with androgenetic alopecia
J Am Acad Dermatol
(1998)
The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telegen hair loss in women
J Am Acad Dermatol
Patterned andrgenetic alopecia in women
J Am Acad Dermatol
A randomised placebo controlled trial of 2% and 5% topical minoxidil solutions in the treatment of female pattern hail loss
J Am Acad Dermatol
Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia
J Am Acad Dermatol
Use of cyproterone acetate, finesteride and spironolactone to treat idiopathic hirsutism
Fertil Steril
Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex
Br J Dermatol
Male pattern baldness. Classification and incidence
South Med J
Hair density, hair diameter and the prevalence of female pattern hair loss
Br J Dermatol
Incidence of female androgenetic alopecia (female pattern alopecia)
Dermatol Surg
Psychological characteristics of women with androgenetic alopecia: a controlled study
Br J Dermatol
The psychology of hair loss and its implications for patient care
Clin Dermatol
The effect of hair loss in European men: a survey of four countries
Eur J Dermatol
Perception of men with androgenetic alopecia by women and non bolding men
Int J Dermatol
The effect of hair loss on quality of life
J Eur Acad Dermatol Venereol
Genetic basis of male pattern baldness
J Invest Dermatol
Gene-wide association study of the aromatase gene (CYP19A1) with female pattern hair loss
Br J Dermatol
Male hormone stimulation is prerequisite and an insitant in common baldness
Am J Anat
Physiology of the steroid-thyroid hormone nuclear receptor superfamily
Baillieres Clin Endocrinol Metab
Genetic and pharmacological evidence for more than one human steroid 5-alpha-reductase
J Clin Invest
Cited by (61)
Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome
2023, Toxicology and Applied PharmacologyEfficacy and safety profile of oral spironolactone use for androgenic alopecia: A systematic review
2022, Journal of the American Academy of DermatologySpironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis
2020, Journal of the American Academy of DermatologyCitation Excerpt :This study has several limitations. Given that spironolactone is a long-term medication, the current study only examined 2 years of data surveillance.1,2 Data with a longer surveillance time would be required to assess 5- or 10-year cancer recurrence risk.
Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism
2020, Actas Dermo-SifiliograficasSpironolactone as a relay for cyproterone acetate in hyperandrogenic women
2020, Gynecologie Obstetrique Fertilite et Senologie